Patents
Literature
2 results about "Azelnidipine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Azelnidipine (INN; marketed under the brand name CalBlock — カルブロック) is a dihydropyridine calcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate.
Use of dihydropyridine compounds or salts thereof for the preparation of a medicament for the prevention and / or treatment of HPV infection
The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.
Owner:QINGDAO MARINE BIOPHARMACEUTICAL RES INST
Application of compound Azelnidipine in the preparation of antiviral drugs
ActiveCN121370885BAbility to inhibit replicationwon't hurtOrganic active ingredientsAntiviralsClassical swine fever virus CSFVAdjuvant
This invention discloses the application of the compound Azelnidipine in the preparation of antiviral drugs, relating to the field of biomedical technology. This invention successfully explores the novel application value of the compound Azelnidipine and its pharmaceutically acceptable salts in the prevention and control of African swine fever. Azelnidipine possesses excellent ability to inhibit the replication of African swine fever virus, exerting intervention effects at different stages of viral infection and exhibiting good concentration-dependent action. It also possesses high biocompatibility, causing no significant damage to host cells, thus balancing antiviral efficacy and biocompatibility. Furthermore, this compound can not only be used to prepare various dosage forms of drugs for the prevention and / or treatment of African swine fever virus infection, but can also be extended to serve as an adjuvant for African swine fever vaccines, possessing very broad prospects for industrial application and market value.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)